Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

Edward C. Keystone; Mark C. Genovese; Douglas E. Schlichting; Inmaculada de la Torre; Scott D. Beattie; Terence P. Rooney; Peter C. Taylor

doi:10.3899/jrheum.161161

Research ArticleRheumatoid Arthritis

Open Access

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

Edward C. Keystone, Mark C. Genovese, Douglas E. Schlichting, Inmaculada de la Torre, Scott D. Beattie, Terence P. Rooney and Peter C. Taylor

The Journal of Rheumatology January 2018, 45 (1) 14-21; DOI: https://doi.org/10.3899/jrheum.161161

Edward C. Keystone

From the Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana, USA; Kennedy Institute of Rheumatology and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: Ed.Keystone{at}sinaihealthsystem.ca

Mark C. Genovese

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Douglas E. Schlichting

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Inmaculada de la Torre

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Scott D. Beattie

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Terence P. Rooney

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter C. Taylor

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
References
PDF

PreviousNext

Data supplements

Data Supplement

Files in this Data Supplement:

Data Supplement

PreviousNext

In this issue

The Journal of Rheumatology

Vol. 45, Issue 1

1 Jan 2018

Table of Contents
Table of Contents (PDF)
Index by Author
Editorial Board (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

Message Subject (Your Name) has forwarded a page to you from The Journal of Rheumatology

Message Body (Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis